IDWeek 2021: Clinical Impact of New Data*

Read expert faculty members’ summaries of key HIV studies from IDWeek 2021, including data on 2-drug ART, metabolic outcomes, investigational agents, long-acting injectable agents, survey data of the U=U educational campaign, premature mortality risk, pneumococcal disease in PWH, maternal DTG use, and PrEP.

Eric S. Daar, MD Joseph J. Eron, Jr., MD Darcy Wooten, MD Released: October 19, 2021

Hear unique insights from expert faculty as she presents updates and new HIV data from IDWeek 2021, including 2-drug ART, metabolic outcomes, investigational agents, and survey data of the U=U educational campaign.

Darcy Wooten, MD Released: October 20, 2021

Hear unique insights from expert faculty as he presents updates and new HIV data from IDWeek 2021, including 2-drug ART, metabolic outcomes, investigational agents, and survey data of the U=U educational campaign.

Eric S. Daar, MD Released: October 21, 2021

Managing weight gain and associated metabolic complications is increasingly important for HIV healthcare professionals. Read my take on the implications of studies in these areas from IDWeek 2021.

Darcy Wooten, MD Released: October 28, 2021

Once perceived as unsafe, during the past 3 years, dolutegravir (DTG) has shifted to being recommended as first-line treatment in women trying to conceive and in those who are pregnant. Read my take on the evolution of our use of DTG in women of child-bearing potential.

Joseph J. Eron, Jr., MD Released: November 18, 2021

New 2-drug regimen strategies for people with HIV have disrupted the traditional treatment paradigm of 3-drug regimens. Read my take on what these data from IDWeek 2021 mean for practice in Western Europe.

Karine Lacombe, MD, PhD Released: November 2, 2021

Gaps in PrEP delivery and uptake remain prevalent. Here’s how we can use information from IDWeek 2021 on evaluation of delivery gaps—and possible solutions—to help us improve PrEP initiation.

Nelly Mugo, MBChB, MMed, MPH Released: October 29, 2021

There is a need for deeper understanding of how 2-drug regimens and metabolic complications affect Latin American PWH given the need for effective ART that does not worsen obesity in a region where this can be prevalent.

Brenda E. Crabtree Ramírez, MD Released: October 28, 2021

Listen to expert insights from Darcy Wooten, MD, on updates and new HIV data from IDWeek 2021, including 2-drug ART, metabolic outcomes, investigational agents, and survey data of the U=U educational campaign.

Darcy Wooten, MD Released: October 11, 2021